Recent Updates
Recently added Catalysts
VTRS Neutral Sentiment Score: 60/100

Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023 Viatris Inc. (NASDAQ: VTRS) plans to report its second quarter 2023 financial results on Monday, August 7 before the open of the U.S. financial...

Key Takeaway: Viatris Inc. (NASDAQ: VTRS) has announced it will report its second quarter 2023 financial results on August 7, 2023, prior to the opening of U.S. financial markets. CEO Scott A. Smith, President Rajiv Malik, and CFO Sanjeev Narula will host a webcast at 8:30 a.m. ET to discuss the results. Investors and the public can access the webcast live or through a replay on the company's investor website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Viatris is set to release its financial results, indicating transparency.
  • The upcoming webcast provides an opportunity for direct communication with stakeholders.
  • Viatris has a diverse portfolio of over 1,400 approved molecules.

Full Press Release Details

PITTSBURGH , June 28, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) plans to report its second quarter 2023 financial results on Monday, August 7 before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith , President Rajiv Malik , and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on August 7 to discuss the results.
Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800-274-8461 or 203-518-9783 for international callers (Conference ID: VTRSQ223). A replay of the webcast also will be available on the website.
About Viatris Viatris Inc. (NASDAQ: VTRS ) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh , Shanghai and Hyderabad, India . Learn more at viatris.com and investor.viatris.com , and connect with us on Twitter , LinkedIn , Instagram and YouTube .
SOURCE Viatris Inc.

21 %

About Viatris Inc.

Ticker Symbol: VTRS
Exchange: NASDAQ
Mission: Empower people worldwide to live healthier at every stage of life
Patient Reach: ~1 billion patients annually
Global Centers: Pittsburgh, Shanghai, Hyderabad

Frequently Asked Questions

When will Viatris report its Q2 2023 financial results?

Viatris will report its Q2 2023 financial results on August 7, 2023.

Who will host the Viatris Q2 financial results webcast?

CEO Scott A. Smith, President Rajiv Malik, and CFO Sanjeev Narula will host it.

Where can I listen to the Viatris earnings call?

The earnings call can be accessed at investor.viatris.com or via phone.

What is Viatris' core mission?

Viatris aims to empower global health by providing access to medicines.

How many countries does Viatris serve?

Viatris delivers high-quality medicines in over 165 countries and territories.

Last updated: Jun 28, 2023